Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Am Heart J

Retrieve available abstracts of 105 articles:
HTML format

Single Articles

    July 2022
  1. SCHOLTEN J, Jansen WPJ, Horsthuis T, Mahes AD, et al
    Six-lead device superior to single-lead smartwatch ECG in atrial fibrillation detection.
    Am Heart J. 2022 Jul 15. pii: S0002-8703(22)00143.
    PubMed     Abstract available

    June 2022
  2. DIXON D, Patel J, Spence R, Talasaz A, et al
    Select Drug-Drug Interactions with Colchicine and Cardiovascular Medications: A Review.
    Am Heart J. 2022 Jun 14. pii: S0002-8703(22)00126.
    PubMed     Abstract available

  3. MAGNANI JW, Ferry D, Swabe G, Martin D, et al
    Design and rationale of the Mobile health intervention for rural atrial fibrillation.
    Am Heart J. 2022 Jun 9. pii: S0002-8703(22)00117.
    PubMed     Abstract available

    The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease - Fact or fallacy.
    Am Heart J. 2022;248:163-164.

    May 2022
  5. AULIN J, Hijazi Z, Lindback J, Alexander JH, et al
    Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.
    Am Heart J. 2022 May 12. pii: S0002-8703(22)00091.
    PubMed     Abstract available

  6. OKAZAKI O, Higashino Y, Yokoya K, An Y, et al
    Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis.
    Am Heart J. 2022 May 11. pii: S0002-8703(22)00094.
    PubMed     Abstract available

  7. GWAG HB, Kim HR, Park SJ, Kim J, et al
    The efficacy of single-lead implantable cardioverter-defibrillator with atrial sensing dipole to detect atrial fibrillation and to reduce inappropriate therapy according to atrial sensing ON or OFF: Rationale and design of the SMART-CONTROL study, a p
    Am Heart J. 2022 May 11. pii: S0002-8703(22)00090.
    PubMed     Abstract available

  8. LOPEZ-GALVEZ R, Marin F, Rivera-Caravaca JM
    Predicting heart failure in atrial fibrillation patients: What about using biomarkers?
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00092.

  9. HUIJBOOM HFM, Maarse M, Aarnink E, van Dijk VF, et al
    COMPARE LAAO: Rationale and design of the randomized controlled trial 'COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagul
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00085.
    PubMed     Abstract available

  10. WAZNI O, Boersma L, Healey JS, Mansour M, et al
    Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation: Rationale and Design of the OPTION randomized trial.
    Am Heart J. 2022 May 5. pii: S0002-8703(22)00088.
    PubMed     Abstract available

  11. GAO W, Zhong X, Ma Y, Huang D, et al
    A Randomized Multicenter Trial to Evaluate Early Invasive Strategy for Patients with Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours from Symptom Onset: protocol of the RESCUE-MI study.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00087.
    PubMed     Abstract available

    April 2022
  12. SINGER DE, Atlas SJ, Go AS, Lopes RD, et al
    ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor.
    Am Heart J. 2022 Apr 23. pii: S0002-8703(22)00080.
    PubMed     Abstract available

    February 2022
  13. NAIR GM, Birnie DH, Wells GA, Nery PB, et al
    Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence (AWARE) Trial: Design and Rationale.
    Am Heart J. 2022 Feb 24. pii: S0002-8703(22)00043.
    PubMed     Abstract available

  14. JONES AE, McCarty MM, Brito JP, Noseworthy PA, et al
    Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation: Rationale and Design of the RED-AF study.
    Am Heart J. 2022 Feb 23. pii: S0002-8703(22)00042.
    PubMed     Abstract available

  15. CHO MS, Kang DY, Oh YS, Lee CH, et al
    Edoxaban-Based Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Stable Coronary Disease: Rationale and Design of the Randomized EPIC-CAD Trial.
    Am Heart J. 2022 Feb 8. pii: S0002-8703(22)00023.
    PubMed     Abstract available

  16. CHANG PC, Wen MS, Chou CC, Wang CC, et al
    Atrial Fibrillation Detection Using Ambulatory Smartwatch Photoplethysmography and Validation with Simultaneous Holter Recording.
    Am Heart J. 2022 Feb 4. pii: S0002-8703(22)00028.
    PubMed     Abstract available

    January 2022
  17. BAYKANER T, Pundi K, Lin B, Lu Y, et al
    The ENHANCE-AF Clinical Trial to Evaluate an Atrial Fibrillation Shared Decision-Making Pathway: Rationale and Study Design.
    Am Heart J. 2022 Jan 26. pii: S0002-8703(22)00013.
    PubMed     Abstract available

  18. KLINGENBERG R, Stahli BE, Heg D, Denegri A, et al
    Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial.
    Am Heart J. 2022 Jan 26. pii: S0002-8703(22)00010.
    PubMed     Abstract available

  19. ECKMAN MH, Wise R, Knochelmann C, Mardis R, et al
    Electronic Health Record-Embedded Decision Support to Reduce Stroke Risk in Patients with Atrial Fibrillation - Study Protocol.
    Am Heart J. 2022 Jan 23. pii: S0002-8703(22)00012.
    PubMed     Abstract available

  20. GENCER B, Eisen A, Berger D, Nordio F, et al
    Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.
    Am Heart J. 2022 Jan 3. pii: S0002-8703(21)00499.
    PubMed     Abstract available

  21. FARJAT AE, Virdone S, Thomas LE, Kakkar AK, et al
    The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries.
    Am Heart J. 2022;243:110-121.
    PubMed     Abstract available

    December 2021
  22. HIGGINS AY, Annapureddy AR, Wang Y, Minges KE, et al
    Risk and Predictors of Mortality After Implantable Cardioverter-Defibrillator Implantation in Patients with Sarcoid Cardiomyopathy.
    Am Heart J. 2021 Dec 27. pii: S0002-8703(21)00491.
    PubMed     Abstract available

  23. ULLAL AJ, Holmes DN, Lytle BL, Matsouaka RA, et al
    Achievement and Quality Measure Attainment in Patients Hospitalized with Atrial Fibrillation: Results from the Get With The Guidelines(R) - Atrial Fibrillation (GWTG-AFIB) Registry.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00475.
    PubMed     Abstract available

  24. PAVLOVIC N, Chierchia GB, Velagic V, Hermida JS, et al
    Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms.
    Am Heart J. 2021;242:103-114.
    PubMed     Abstract available

    November 2021
  25. STEINBERG BA, Li Z, Shrader P, Chew DS, et al
    Clinical Investigations Bimodal Distribution of Atrial Fibrillation Burden in 3 Distinct Cohorts: What is 'Paroxysmal' Atrial Fibrillation?
    Am Heart J. 2021 Nov 24. pii: S0002-8703(21)00464.
    PubMed     Abstract available

  26. ANTONIO GUTIERREZ J, Ruff CT, Aday AW, Gu L, et al
    Electronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation.
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00452.
    PubMed     Abstract available

  27. CHEW DS, Li Z, Steinberg BA, O'Brien E, et al
    Association between Economic and Arrhythmic Burden of Paroxysmal Atrial Fibrillation in Patients with Cardiac Implanted Electronic Devices.
    Am Heart J. 2021 Nov 17. pii: S0002-8703(21)00450.
    PubMed     Abstract available

  28. MERT GO, Babayigit E, Gorenek B
    The value of performing thorough echocardiography in patients with coronary heart disease and atrial fibrillation.
    Am Heart J. 2021;241:121.

  29. TOMASDOTTIR M, Held C, Wallentin L, Hijazi Z, et al
    Natriuretic peptides and incident atrial fibrillation.
    Am Heart J. 2021;241:120.

  30. DAILEY-SCHWARTZ AL, Dyal JA, Mahle WT, Oster ME, et al
    Implementation of a practice plan for the outpatient cardiac evaluation of children after acute SARS-CoV-2 infection and a report of outcomes.
    Am Heart J. 2021;241:83-86.
    PubMed     Abstract available

    October 2021
  31. AKDIS D, Chen L, Saguner AM, Zhang N, et al
    Novel Plasma Biomarkers Predicting Biventricular Involvement in Arrhythmogenic Right Ventricular Cardiomyopathy: Novel Biomarkers in ARVC.
    Am Heart J. 2021 Oct 28. pii: S0002-8703(21)00441.
    PubMed     Abstract available

  32. ARITA VA, Santema BT, De With RR, Nguyen BO, et al
    Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study.
    Am Heart J. 2021 Oct 21. pii: S0002-8703(21)00435.
    PubMed     Abstract available

  33. PICCINI JP, Ahlsson A, Dorian P, Gillinov MA, et al
    Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study.
    Am Heart J. 2021 Oct 20. pii: S0002-8703(21)00366.
    PubMed     Abstract available

  34. RASMUSSEN PV, Blanche P, Dalgaard F, Gislason GH, et al
    Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events: Rasmussen et al: Electrical cardioversion and bradycardia.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00434.
    PubMed     Abstract available

  35. CHIENG D, Sugumar H, Ling LH, Segan L, et al
    Catheter Ablation for Persistent Atrial Fibrillation: a Multicentre Randomised Trial of Pulmonary Vein Isolation (PVI) versus PVI with Posterior Left Atrial Wall Isolation (PWI) - the CAPLA Study: CAPLA: randomised trial for persistent AF.
    Am Heart J. 2021 Oct 4. pii: S0002-8703(21)00245.
    PubMed     Abstract available

    September 2021
  36. KORSHOLM K, Damgaard D, Valentin JB, Packer EJS, et al
    Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial.
    Am Heart J. 2021 Sep 16. pii: S0002-8703(21)00226.
    PubMed     Abstract available

  37. BURNHAM TS, May HT, Bair TL, Anderson JA, et al
    Long-term Outcomes in Patients Treated with Flecainide for Atrial Fibrillation with Stable Coronary Artery Disease.
    Am Heart J. 2021 Sep 16. pii: S0002-8703(21)00211.
    PubMed     Abstract available

  38. KIM K, Yang PS, Jang E, Yu HT, et al
    Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study.
    Am Heart J. 2021 Sep 1. pii: S0002-8703(21)00224.
    PubMed     Abstract available

    August 2021
  39. DAWWAS GK, Barnes GD, Dietrich E, Cuker A, et al
    Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation A population-based analysis.
    Am Heart J. 2021 Aug 24. pii: S0002-8703(21)00212.
    PubMed     Abstract available

  40. BONNESEN MP, Diederichsen SZ, Isaksen JL, Frederiksen KS, et al
    Atrial Fibrillation Burden and Cognitive Decline in Elderly Patients Undergoing Continuous Monitoring.
    Am Heart J. 2021 Aug 21. pii: S0002-8703(21)00204.
    PubMed     Abstract available

  41. HAWKINS NM, Er L, Sandhu RK, Kaul P, et al
    Validity of different dose reduction criteria for apixaban.
    Am Heart J. 2021;238:12-15.
    PubMed     Abstract available

    July 2021
  42. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    PubMed     Abstract available

  43. FREYER L, von Stulpnagel L, Spielbichler P, Sappler N, et al
    Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based Bavarian Alternative Detection of Atrial Fibrillation (eBRAVE-AF) trial.
    Am Heart J. 2021 Jul 9. pii: S0002-8703(21)00164.
    PubMed     Abstract available

    June 2021
  44. KUMAR N, Xu H, Garg N, Pandey A, et al
    Patient Characteristics, Care Patterns, and Outcomes of Atrial Fibrillation Associated Hospitalizations in Patients with Chronic Kidney Disease and End-Stage Renal Disease.
    Am Heart J. 2021 Jun 30. pii: S0002-8703(21)00175.
    PubMed     Abstract available

  45. WHEELOCK KM, Kratz A, Lathkar-Pradhan S, Najarian K, et al
    Association between Symptoms, Affect and Heart Rhythm in Patients with Persistent or Paroxysmal Atrial Fibrillation: An Ambulatory Pilot Study.
    Am Heart J. 2021 Jun 19. pii: S0002-8703(21)00150.
    PubMed     Abstract available

  46. SZUMMER K, Perino AC, Fan J, Kothari M, et al
    Association of kidney function and atrial fibrillation progression to clinical outcomes in patients with cardiac implantable electronic devices.
    Am Heart J. 2021 Jun 9. pii: S0002-8703(21)00149.
    PubMed     Abstract available

    May 2021
  47. KITTIPIBUL V, Blumer V, Hernandez GA, Fudim M, et al
    Pre-operative Atrial Fibrillation and Early Right Ventricular Failure after Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.
    Am Heart J. 2021 May 23. pii: S0002-8703(21)00138.
    PubMed     Abstract available

  48. YAO X, Attia ZI, Behnken EM, Walvatne K, et al
    Batch Enrollment for an Artificial Intelligence-Guided Intervention to Lower Neurologic Events in Patients with Undiagnosed Atrial Fibrillation (BEAGLE): Rationale and design of a digital clinical trial.
    Am Heart J. 2021 May 22. pii: S0002-8703(21)00135.
    PubMed     Abstract available

  49. HESS PL, Gosch KL, Jani SM, Varosy PD, et al
    Use of Oral Anticoagulants in Patients with Valvular Atrial Fibrillation: Findings From the NCDR PINNACLE Registry(R).
    Am Heart J. 2021 May 22. pii: S0002-8703(21)00120.
    PubMed     Abstract available

  50. GRUBB CS, Truby LK, Topkara VK, Bohnen MS, et al
    Advanced Heart Failure Patients Supported with Ambulatory Inotropic Therapy: What Defines Success of Therapy?
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00121.
    PubMed     Abstract available

  51. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    PubMed     Abstract available

    April 2021
  52. LUBITZ SA, Faranesh AZ, Atlas SJ, McManus DD, et al
    Rationale and Design of a Large Population Study to Validate Software for the Assessment of Atrial Fibrillation from Data Acquired by a Consumer Tracker or Smartwatch: The Fitbit Heart Study.
    Am Heart J. 2021 Apr 15. pii: S0002-8703(21)00093.
    PubMed     Abstract available

  53. MARTIN AC, Hausleiter J, Karam N
    Intra-procedural unfractionated heparin monitoring and uninterrupted direct oral anticoagulants: An unheeded issue in transcatheter mitral valve repair procedures.
    Am Heart J. 2021;234:136-137.

    March 2021
  54. KIVINIEMI T, Bustamante-Munguira J, Olsson C, Jeppsson A, et al
    A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery - LAA-CLOSURE trial protocol.
    Am Heart J. 2021 Mar 30. pii: S0002-8703(21)00087.
    PubMed     Abstract available

  55. TURAKHIA M, Sundaram V, Smith SN, Ding V, et al
    Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban
    Am Heart J. 2021 Mar 4. pii: S0002-8703(21)00065.
    PubMed     Abstract available

  56. CHERY GS, Kamp N, Kosinski AS, Schmidler GS, et al
    Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement.
    Am Heart J. 2021;233:151-152.

  57. DISERTORI M, Mase M, Rigoni M, Ravelli F, et al
    The paradox of implantable cardioverter-defibrillator: When guidelines may play against care improvement.
    Am Heart J. 2021;233:149-150.

  58. CHEW DS, Sacks NC, Emden MR, Preib MT, et al
    Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States.
    Am Heart J. 2021;233:132-140.
    PubMed     Abstract available

    February 2021
  59. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    PubMed     Abstract available

  60. BLUMER V, Rivera M, Corbalan R, Becker RC, et al
    Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
    Am Heart J. 2021 Feb 8. pii: S0002-8703(21)00036.
    PubMed     Abstract available

    January 2021
  61. SEN S, Redd K, Trivedi T, Moss K, et al
    Periodontal Disease, Atrial Fibrillation and Stroke.
    Am Heart J. 2021 Jan 24. pii: S0002-8703(21)00013.
    PubMed     Abstract available

  62. DE GROOT JR, Ruff CT, Murphy SA, Hamershock RA, et al
    Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study.
    Am Heart J. 2021 Jan 22. pii: S0002-8703(21)00017.
    PubMed     Abstract available

  63. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    PubMed     Abstract available

  64. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Corrigendum to "Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry sub-analysis" [Am Heart J, 223 (2020), 23-33].
    Am Heart J. 2021 Jan 8. pii: S0002-8703(20)30404.

  65. TOMASDOTTIR M, Held C, Hadziosmanovic N, Westerbergh J, et al
    Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease.
    Am Heart J. 2021 Jan 2. pii: S0002-8703(20)30425.
    PubMed     Abstract available

  66. TSENG WC, Huang CN, Chiu SN, Lu CW, et al
    Long-term outcomes of arrhythmia and distinct electrophysiological features in congenitally corrected transposition of the great arteries in an Asian cohort.
    Am Heart J. 2021;231:73-81.
    PubMed     Abstract available

  67. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    PubMed     Abstract available

    December 2020
  68. ROME BN, Gagne JJ, Avorn J, Kesselheim AS, et al
    Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study.
    Am Heart J. 2020 Dec 21. pii: S0002-8703(20)30412.
    PubMed     Abstract available

  69. CARNICELLI AP, Hong H, Giugliano RP, Connolly SJ, et al
    Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple instit
    Am Heart J. 2020 Dec 6. pii: S0002-8703(20)30401.
    PubMed     Abstract available

  70. KHAN H, Hanif M, Khan MA, Mirza E, et al
    Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice.
    Am Heart J. 2020;230:101.

    November 2020
  71. OVERWYK KJ, Yin X, Tong X, King SMC, et al
    Defect-free Care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018.
    Am Heart J. 2020 Nov 27. pii: S0002-8703(20)30392.
    PubMed     Abstract available

  72. PERETTO G, De Luca G, Campochiaro C, Palmisano A, et al
    Telemedicine in myocarditis: Evolution of a mutidisciplinary "disease unit" at the time of COVID-19 pandemic.
    Am Heart J. 2020;229:121-126.
    PubMed     Abstract available

  73. LACHTRUPP CL, Valente AM, Gurvitz M, Landzberg MJ, et al
    Interobserver agreement of the anatomic and physiological classification system for adult congenital heart disease.
    Am Heart J. 2020;229:92-99.
    PubMed     Abstract available

  74. YANNOPOULOS D, Kalra R, Kosmopoulos M, Walser E, et al
    Rationale and methods of the Advanced R(2)Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial.
    Am Heart J. 2020;229:29-39.
    PubMed     Abstract available

    October 2020
  75. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    PubMed     Abstract available

  76. NATHAN AS, Yang L, Geng Z, Dayoub EJ, et al
    Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair.
    Am Heart J. 2020;232:1-9.
    PubMed     Abstract available

  77. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available

  78. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    PubMed     Abstract available

  79. IKENOUCHI T, Inaba O, Takamiya T, Inamura Y, et al
    The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30347.
    PubMed     Abstract available

  80. GUIMARAES HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, et al
    A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30277.
    PubMed     Abstract available

  81. GONG IY, Atzema CL, Lega IC, Austin PC, et al
    Levothyroxine dose and risk of atrial fibrillation: a nested case-control study.
    Am Heart J. 2020 Oct 3. pii: S0002-8703(20)30272.
    PubMed     Abstract available

    August 2020
  82. KAWAKAMI H, Nolan MT, Phillips K, Scuffham PA, et al
    Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30238.
    PubMed     Abstract available

  83. KWON S, Lee SR, Choi EK, Choe WS, et al
    Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Am Heart J. 2020;229:81-91.
    PubMed     Abstract available

  84. MIRWAIS M, Reynolds M
    Extending physicians' reach in grasping AF symptoms.
    Am Heart J. 2020;226:250-251.

  85. KAHN PA, Gruen J, Thomas A, Ahmad T, et al
    Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system.
    Am Heart J. 2020;226:232-234.

    July 2020
  86. AL-KHATIB SM, Pokorney SD, Al-Khalidi HR, Haynes K, et al
    Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillati
    Am Heart J. 2020;229:110-117.
    PubMed     Abstract available

    June 2020
  87. PRASAD A, Panhwar S, Hendel RC, Sheikh O, et al
    COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports.
    Am Heart J. 2020;226:174-187.
    PubMed     Abstract available

  88. DELURGIO DB, Ferguson E, Gill J, Blauth C, et al
    Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE Trial): Rationale and design.
    Am Heart J. 2020;224:182-191.
    PubMed     Abstract available

    May 2020
  89. DEHGHANI P, Davidson LJ, Grines CL, Nayak K, et al
    North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.
    Am Heart J. 2020 May 16. pii: S0002-8703(20)30142.
    PubMed     Abstract available

  90. HA ACT, Stewart J, Klein G, Roy D, et al
    Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?
    Am Heart J. 2020;226:152-160.
    PubMed     Abstract available

  91. KATSUMATA Y, Kimura T, Kohsaka S, Ikemura N, et al
    Discrepancy in recognition of symptom burden among patients with atrial fibrillation.
    Am Heart J. 2020 May 6. pii: S0002-8703(20)30120.
    PubMed     Abstract available

  92. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    PubMed     Abstract available

  93. WEIR MR, Ashton V, Moore KT, Shrivastava S, et al
    Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease".
    Am Heart J. 2020;223:111-112.

  94. SHOAR S, Shoar N, Naderan M, Modukuru VR, et al
    Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".
    Am Heart J. 2020;223:110.

    April 2020
  95. JACKSON LR 2ND, Kim S, Blanco R, Thomas L, et al
    Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2020;226:85-93.
    PubMed     Abstract available

  96. WALLACE BC, Allen LA, Knoepke CE, Glasgow RE, et al
    A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data.
    Am Heart J. 2020;226:161-173.
    PubMed     Abstract available

  97. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Corrigendum to "Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis" Am Heart J (2020).
    Am Heart J. 2020 Apr 13. pii: S0002-8703(20)30092.

    March 2020
  98. KARTHIKEYAN G, Connolly SJ, Ntsekhe M, Benz A, et al
    The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Am Heart J. 2020;225:69-77.
    PubMed     Abstract available

  99. THIBERT MJ, Hawkins NM, Andrade JG
    Clinical decision support for atrial fibrillation in primary care: Steps forward.
    Am Heart J. 2020;224:54-56.

  100. COX JL, Parkash R, Foster GA, Xie F, et al
    Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool.
    Am Heart J. 2020;224:35-46.
    PubMed     Abstract available

  101. MIYAZAKI S, Horie T, Hachiya H, Hasegawa K, et al
    The mechanisms of recurrent atrial arrhythmias after second-generation cryoballoon ablation.
    Am Heart J. 2020;221:29-38.
    PubMed     Abstract available

    February 2020
  102. HERNANDEZ-OJEDA J, Arbelo E, Jorda P, Borras R, et al
    The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope.
    Am Heart J. 2020;220:213-223.
    PubMed     Abstract available

  103. ALI-AHMED F, Dalgaard F, Al-Khatib SM
    Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management.
    Am Heart J. 2020;220:29-40.
    PubMed     Abstract available

    January 2020
  104. LU DY, Ventoulis I, Liu H, Kudchadkar SM, et al
    Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
    Am Heart J. 2020;219:58-69.
    PubMed     Abstract available

    December 2019
  105. MUHLESTEIN JB, Anderson JL, Bethea CF, Severance HW, et al
    Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.
    Am Heart J. 2019;221:125-135.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.